Colchicine helps calm the inflammatory response caused by urate crystals in a joint. It is used for acute gout attacks in adults, with 500 microgram tablets supplied for individually prescribed…
Colchicine helps calm the inflammatory response caused by urate crystals in a joint. It is used for acute gout attacks in adults, with 500 microgram tablets supplied for individually prescribed dosing. The medicine reduces inflammation but does not lower uric acid.
Colchicine is an anti-inflammatory treatment for gout. The active ingredient in these tablets is colchicine at a strength of 500 micrograms per tablet. This is the component responsible for the anti-inflammatory action used in gout.
Colchicine is an anti-inflammatory treatment for gout. During a gout flare, urate crystals collect in a joint and activate immune cells. This produces swelling, heat, tenderness and pain. Colchicine reduces the inflammatory reaction around those crystals, helping the flare settle.
It treats the inflammation of gout rather than removing the urate crystals or correcting the high uric acid level that caused them. Long-term urate-lowering treatment has a different purpose and may be prescribed separately.
Colchicine works best when treatment begins early in a flare, following the prescribed regimen. The exact amount per intake is set individually rather than being one fixed number for every person. A prescriber may take account of kidney function, liver function, age, other medicines and the severity of symptoms.
The medicine is not a general painkiller for every type of joint pain. Its role is linked to crystal-driven inflammation in conditions such as gout. NICE guidance describes anti-inflammatory treatment, including colchicine, as an option for managing gout flares when clinically suitable [1].
Colchicine can reduce the swelling and pain of an existing flare, but it does not lower blood urate. For example, a person may feel better after a flare while the tendency to form urate crystals remains.
This distinction matters because symptom relief and prevention are separate treatment goals. A clinician may use colchicine for an acute episode and consider urate-lowering treatment, such as allopurinol, to reduce future attacks.
The tablets contain:
Colchicine enters inflammatory cells and interferes with microtubules. Microtubules are tiny internal structures that help cells move, change shape and release chemical signals. By disrupting these processes, colchicine reduces the movement and activation of white blood cells around urate crystals.
The result is less inflammatory signalling in the affected joint. Colchicine does not dissolve the crystals directly and does not lower the uric acid concentration in the bloodstream. Its action is directed at the body’s response to the crystals.
The MHRA product information warns that colchicine toxicity can develop when exposure becomes excessive, especially with impaired kidney or liver function and interacting medicines [2]. This explains why apparently small changes in dose or drug combinations can matter.
Colchicine differs from treatments that lower urate production or increase urate excretion. It acts during the inflammatory process, while preventive medicines work on the longer-term biochemical cause of recurrent gout.
Colchicine and allopurinol can both appear in a gout treatment plan, but they are not interchangeable.
| Treatment | Main role | Key distinction |
|---|---|---|
| Colchicine | Controls inflammation during a gout flare | Does not lower uric acid |
| Allopurinol | Lowers uric acid to prevent future attacks | Does not provide the same immediate anti-inflammatory role |
Colchicine targets the inflammatory response to urate crystals. It may be prescribed during an acute flare or in selected situations when preventive urate-lowering treatment is being started or adjusted.
The regimen is individualised. A person should not use leftover tablets for a new episode without confirming the intended plan, because the suitable amount can change with age, organ function and interacting medicines.
Allopurinol reduces uric acid production by inhibiting xanthine oxidase. Its purpose is long-term prevention of recurrent gout and urate deposition, rather than direct treatment of pain during a flare.
Starting or adjusting allopurinol requires a planned regimen and follow-up. Some patients may receive colchicine alongside urate-lowering treatment for a period, since changes in urate levels can coincide with further flares.
Colchicine calms the immune response. Allopurinol changes urate production. A prescriber may use one, the other or both at different stages, depending on the person’s gout history, urate level, kidney function and treatment tolerance.
Several avoidable errors can make treatment less safe:
A common practical mistake is focusing only on the painful joint. The stomach and bowel may provide the earliest warning that colchicine exposure is too high.
Some medicines can increase colchicine concentrations by affecting enzymes or transport proteins involved in its clearance. Examples include certain antibiotics used for infections, some medicines for heart conditions and selected cholesterol-lowering treatments.
Colchicine should not be used without specific prescriber approval if you have severe kidney or liver problems, a serious blood or bone marrow condition, an allergy to colchicine, severe stomach or bowel symptoms, or a previous serious reaction to the medicine.
People with kidney or liver problems may clear colchicine more slowly. This can increase exposure even when the tablet strength has not changed. The prescriber may choose a different regimen or another treatment.
Pregnancy and breastfeeding require an individual risk assessment. Tell the prescriber about pregnancy, planned pregnancy or breastfeeding before treatment begins.
Tell the prescriber about every medicine, including occasional treatments and herbal products. Do not start or stop a suspected interacting medicine without medical direction.
Digestive symptoms are the main early adverse effects associated with colchicine. The risk rises when the dose is too high, doses are taken too close together, kidney or liver clearance is reduced, or an interacting medicine raises colchicine levels.
Possible effects include:
Mild symptoms still deserve attention because worsening gastrointestinal effects may signal excessive exposure. Severe diarrhoea or vomiting can also cause dehydration, which may make illness harder to manage.
Do not treat severe symptoms by taking an anti-diarrhoeal medicine and continuing colchicine without clinical advice. Further doses may need to be stopped while the situation is assessed.
Rare but serious toxicity can affect the blood-forming tissues of the bone marrow. Warning symptoms may include unusual bruising, bleeding, fever, repeated infections, sore throat, mouth ulcers or marked weakness.
These symptoms require urgent medical assessment. Blood tests may be needed to check blood-cell counts and organ function. Bone marrow disease is not a routine effect, yet the possibility makes persistent or unusual symptoms clinically significant.
Toxicity may progress beyond the first digestive symptoms. Later complications can involve severe weakness, muscle injury, nerve problems, kidney damage or dangerous changes in blood cells.
A suspected overdose requires urgent medical help even if the person feels well. Do not wait for symptoms to appear, take a counter-dose or attempt home treatment.
The FDA prescribing information also describes serious colchicine toxicity after excessive dosing and interactions, supporting the need for rapid assessment after a suspected overdose [3].
In clinical practice, physicians usually focus on three points: early treatment of the flare, strict adherence to the individual regimen and recognition of digestive toxicity. Colchicine can be useful when an anti-inflammatory option is needed, but its narrow safety margin means that more tablets do not equal better treatment.
Doctors also review kidney function, liver function and the full medication list before repeating treatment. A patient who has tolerated colchicine previously may still face a different risk after a new antibiotic or a change in kidney function.
The practical expectation is symptom control, not a permanent correction of urate metabolism. Recurrent attacks often prompt discussion of long-term urate management rather than repeated self-treatment with colchicine.
The best time depends on the prescribed regimen and the stage of the gout flare. Colchicine should be taken at the times instructed by the prescriber, with doses spaced exactly as directed rather than concentrated at one point in the day. MHRA product information updated in 2024 emphasises dose limits and interaction precautions for colchicine. Taking it with food may be suitable for some people who experience stomach upset, but the prescribed instructions take priority. Contact a pharmacist or prescriber if the timing is unclear.
Colchicine does not usually create a direct sedative effect, yet pain, nausea, diarrhoea, weakness or dizziness may reduce concentration. Do not drive or operate machinery if you feel unwell or unable to respond safely. NHS medicine advice available in 2025 supports judging fitness to drive by the symptoms caused by the medicine and the underlying illness. Severe weakness or confusion needs urgent assessment rather than continued work with machinery.
Colchicine reduces inflammation around urate crystals during a gout flare. Allopurinol lowers uric acid production and is used for prevention over a longer period. NICE gout guidance from 2022 describes urate-lowering treatment as part of prevention planning, while colchicine has a different anti-inflammatory role. The two medicines may be used in the same treatment plan, but neither should be substituted for the other without prescriber direction.
Alcohol can increase the likelihood of gout flares by affecting urate balance and may worsen dehydration or stomach upset during an attack. It does not create a simple fixed rule that applies to every patient taking colchicine. The WHO guidance on alcohol and health, reviewed in 2023, supports limiting alcohol where it worsens a relevant medical condition. Avoid alcohol during severe nausea, vomiting or diarrhoea and follow the specific advice given with your gout treatment plan.
Severe kidney impairment, significant liver impairment, serious blood disorders and known colchicine allergy can rule out treatment or require specialist control. Colchicine may also be unsuitable with medicines that substantially raise its concentration. EMA product information available in 2024 highlights the need to assess renal function, hepatic function and interacting medicines before use. A suspected overdose is an emergency regardless of whether symptoms have started.
Stop taking further doses and seek urgent clinical advice if diarrhoea or vomiting is severe, persistent or accompanied by weakness or abdominal pain. These symptoms can be early signs of excessive colchicine exposure. Do not take an additional tablet to compensate for fluid loss or continue the course without advice. The MHRA safety information from 2024 links gastrointestinal symptoms with the need to consider colchicine toxicity and further assessment.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Based on 4 reviews
I used the 500 microgram tablets during a flare after my GP prescribed them. The swelling eased over the next day, but I had loose stools, so I did not take another dose until I had received advice.
Derby 27 Oct 2026The tablets helped with the sharp pain in my toe. I had previously assumed colchicine lowered uric acid, so the explanation about long-term prevention was useful. I still needed a separate plan for recurring attacks.
York 1 Oct 2026My first day was manageable, although I felt nauseated after taking the tablets. I contacted the surgery rather than adding more, and the regimen was adjusted around my kidney results.
Wolverhampton 18 Oct 2026I found treatment easier when I took the tablets exactly as prescribed. The flare did not disappear straight away, and I initially expected faster relief, but the joint was less swollen after continued clinical management.
Edinburgh 9 Oct 2026
